Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other Non-Current Liabilities (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Other Non-Current Liabilities for 11 consecutive years, with $3.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Liabilities fell 91.07% year-over-year to $3.2 million, compared with a TTM value of $3.2 million through Sep 2025, down 91.07%, and an annual FY2024 reading of $36.6 million, down 11.35% over the prior year.
  • Other Non-Current Liabilities was $3.2 million for Q3 2025 at Spyre Therapeutics, down from $16.5 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $41.3 million in Q4 2023 and bottomed at $8000.0 in Q1 2022.
  • Average Other Non-Current Liabilities over 5 years is $18.8 million, with a median of $18.6 million recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities surged 795.65% in 2021, then plummeted 96.12% in 2022.
  • Year by year, Other Non-Current Liabilities stood at $16000.0 in 2021, then crashed by 50.0% to $8000.0 in 2022, then surged by 516275.0% to $41.3 million in 2023, then dropped by 11.35% to $36.6 million in 2024, then tumbled by 91.18% to $3.2 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for SYRE at $3.2 million in Q3 2025, $16.5 million in Q1 2025, and $36.6 million in Q4 2024.